Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | PPOX | P50336 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL31741821 | 0.97 | DTYMK (0.66) | DTYMKTSHRCASP6MEN1KMT2A | |
| SCHEMBL28277467 | 0.83 | SIRT6 (0.49) | DTYMKMEN1KMT2ALMNATDP1 | |
| SCHEMBL143541 | 0.82 | DTYMK (1.00) | DTYMKTSHRCASP6MEN1KMT2A | |
| SCHEMBL26775 | 0.82 | DTYMK (1.00) | DTYMKTSHRCASP6MEN1KMT2A | |
| SCHEMBL504562 | 0.82 | DTYMK (0.81) | DTYMKTSHRCASP6MEN1KMT2A | |
| SCHEMBL29353295 | 0.82 | DTYMK (1.00) | DTYMKTSHRCASP6MEN1KMT2A | |
| SCHEMBL29388000 | 0.81 | DTYMK (0.97) | DTYMKTSHRCASP6MEN1KMT2A | |
| SCHEMBL8577281 | 0.81 | DTYMK (0.97) | DTYMKTSHRCASP6MEN1KMT2A | |
| SCHEMBL2470206 | 0.81 | DTYMK (0.78) | DTYMKTSHRCASP6MEN1KMT2A | |
| Propionitrile SCHEMBL5577929 | 0.80 | DTYMK (0.76) | DTYMKTSHRCASP6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079838-A | Preparation method of 2-nitro-5-thiocyanobenzoic acid | — | 2026-05-26 | — | — | CN | claimed |
| EP-4737471-A1 | METHODS FOR THE C-TERMINAL MODIFICATION OF (POLY)PEPTIDES | NUMAFERM GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12577602-B2 | Compositions and methods for peptide production | BIOCATALYST LLC (US) | 2026-03-17 | — | — | US | claimed |
| US-12570688-B2 | Activated cysteine-directed polypeptide ligation technique | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2026-03-10 | — | — | US | claimed |
| EP-3765857-B1 | SEQUENTIAL DIGESTION OF POLYPEPTIDES FOR MASS SPECTROMETRIC ANALYSIS | AMGEN INC (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4150348-B1 | SAMPLE PREPARATION FOR MASS SPECTROMETRY | PREOMICS GMBH (DE) | 2025-11-12 | — | — | EP | claimed |
| US-20250340858-A1 | COMPOSITIONS AND METHODS FOR PREVENTING DEBRIS LAYER FORMATION DURING PHASE SEPARATION IN AN ATPS-SAMPLE LYSATE MIXTURE | PHASE SCIENT INTERNATIONAL LTD (CN) | 2025-11-06 | — | — | US | claimed |
| US-12410461-B2 | Method of preparing clinical samples for nucleic acid amplification | DAY ZERO DIAGNOSTICS, INC. (US) | 2025-09-09 | — | — | US | claimed |
| US-12405275-B2 | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis | AMGEN INC. (US) | 2025-09-02 | — | — | US | claimed |
| US-12319909-B2 | Compositions and methods for ribonucleic acid extraction | Phase Scientific International, Ltd. (CN) | 2025-06-03 | — | — | US | claimed |
| WO-2002086081-A2 | METHODS AND SYSTEMS FOR IDENTIFYING PROTEINS | CARNEGIE MELLON UNIVERSITY (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002082088-A1 | RECOVERY OF ENZYME ACTIVITY FROM ENVELOPED VIRUSES | CAVIDI TECH AB (SE) | 2002-10-17 | — | — | WO | claimed |
| US-20020137119-A1 | Peptides representative of polypeptides of interest and antibodies directed thereagainst, and methods, systems and kits for generating and utilizing each | KATZ EMIL ISRAEL (IL) | 2002-09-26 | — | — | US | claimed |
| EP-1223534-A1 | Peptides representative of polypeptides of interest and antibodies directed thereagainst, and methods, systems and kits for generating and utilizing each | Katz, Emil (IL) | 2002-07-17 | — | — | EP | claimed |
| US-6127150-A | VECTOR FOR THE EFFICIENT EXPRESSION AND ISOLATION OF HETEROLOGOUS PROTEINS | BIONEBRASKA, INC. (US) | 2000-10-03 | — | — | US | claimed |
| US-5656456-A | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | BIONEBRASKA, INC. (US) | 1997-08-12 | — | — | US | claimed |
| US-5635371-A | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | BIONEBRASKA, INC. (US) | 1997-06-03 | — | — | US | claimed |
| US-5589364-A | GENETIC ENGINEERING WITH PROTEINS FOR PROTEASE DEFICIENT MICROBIAL HOST TRANSFORMED WITH EXPRESSION VECTOR HAVING DNA CODES AND GENE EXPRESSION | MAGAININ PHARMACEUTICALS INC. (US) | 1996-12-31 | — | — | US | claimed |
| WO-1996017941-A2 | PRODUCTION OF C-TERMINAL AMIDATED PEPTIDES FROM RECOMBINANT PROTEIN CONSTRUCTS | BIONEBRASKA, INC. (US) | 1996-06-13 | — | — | WO | claimed |
| WO-1996004373-A2 | RECOMBINANT PRODUCTION OF BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS | MAGAININ PHARMACEUTICALS, INC. (US) | 1996-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577602-B2 | Compositions and methods for peptide production | LNPEP, CPN1, PRCP | DTYMK 1889/4885TSHR 1047/4885CASP6 1073/4885 |
| US-12570688-B2 | Activated cysteine-directed polypeptide ligation technique | PTMS, LNPEP, ANPEP | DTYMK 2316/4885TSHR 973/4885CASP6 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.